Advancell
AdvanCell Isotopes is a clinical-stage radiopharmaceutical company developing targeted alpha therapies to treat a broad range of cancers. By combining proprietary lead-212 (²¹²Pb) isotope production technology with precision-targeted delivery, AdvanCell aims to overcome the limitations of conventional radiotherapy and deliver potent, tumour-specific treatments—offering new hope for patients with otherwise untreatable cancers.
Over 18 million people globally are diagnosed with cancer each year, yet many face limited treatment options—especially for aggressive or late-stage tumours.
Conventional therapies often lack precision and come with significant toxicity. AdvanCell’s approach—using targeted alpha therapies powered by lead-212 isotopes—has the potential to deliver highly potent, tumour-specific radiation while sparing healthy tissue, offering new hope for patients with otherwise untreatable cancers.
